Wedbush initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $28 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Eli Lilly downgraded, Lyft upgraded: Wall Street’s top analyst calls
- Promising Prospects for Sagimet Biosciences: Buy Rating Backed by Innovative FASN Inhibitor Platform and Clinical Advancements
- Sagimet Biosciences assumed with a Buy at H.C. Wainwright
- 3 Best Stocks to Buy Now, 7/25/2025, According to Top Analysts
- Sagimet Biosciences initiated with a Buy at Canaccord